Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MPT0G211 是一种具有高效性选择性和口服活性的 HDAC6 抑制剂 (IC50=0.291 nM),具有神经保护作用在人乳腺癌细胞中显示出有抗转移活性。MPT0G211 对 HDAC6 的亲和力是其他 HDAC 亚型的 1000 倍。MPT0G211 可以透过血脑屏障,可用于改善阿尔茨海默病模型中 tau 磷酸化和认知缺陷。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,120 | 现货 | ||
2 mg | ¥ 1,580 | 现货 | ||
5 mg | ¥ 2,480 | 现货 | ||
10 mg | ¥ 3,980 | 现货 | ||
25 mg | ¥ 6,270 | 现货 | ||
50 mg | ¥ 8,460 | 现货 | ||
100 mg | ¥ 11,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,530 | 现货 |
产品描述 | MPT0G211 is a highly selective and orally active HDAC6 inhibitor (IC50=0.291 nM) that has neuroprotective effects and has shown anti-metastatic activity in human breast cancer cells. MPT0G211 has 1,000 times more affinity for HDAC6 than other HDAC subtypes. MPT0G211 can cross the blood-brain barrier and could be used to improve tau phosphorylation and cognitive deficits in Alzheimer's disease models. |
靶点活性 | HDAC6:0.291 μM |
体外活性 |
MPT0G211 (0.1 μM; cells transfected with pCAX APP 695 and pRK5-EGFP-Tau P301L for 24 h) significantly inhibits the phosphorylation of tau Ser396[3]. MPT0G211 inhibits HDAC6/Hsp90 binding, leading to subsequent proteasomal degradation of polyubiquitinated proteins[3]. MPT0G211 significantly decreases the phosphorylation of tau through GSK3β inactivation[3]. MPT0G211 (0.1 μM; 24 hours) significantly attenuates the phosphorylation of tau at Ser396 and Ser404 in both cell lines (SH-SY5Y and Neuro-2a cells transfected for 24 h with pCAX APP 695 and pRK5-EGFP-Tau P301L)[3]. MPT0G211 inhibits the growth of MDA-MB-231 and MCF-7 cells (GI50=16.19 and 5.6 μM, respectively)[2].In AML cells, MPT0G211 potentiates the cytotoxic effects of DOXO by impairing DNA repair machinery and activating Bcl-2-associated X protein (BCL-XL)-dependent cell apoptosis[1]. |
体内活性 |
MPT0G211 (50 mg/kg; oral administration; daily for 3 months) significantly ameliorates spatial memory impairment[3]. MPT0G211 (25 mg/kg; intraperitoneal injection; once daily; day 73 post-tumor injection) reduces the numbers of nodules and lung weights[2]. MPT0G211 treatment not only diminishes tau phosphorylation by inhibiting GSK3β activity but also enhances the acetylation of Hsp90. This leads to the downregulation of HDAC6/Hsp90 binding and facilitates proteasomal degradation of polyubiquitinated phosphorylated tau[3]. |
分子量 | 293.32 |
分子式 | C17H15N3O2 |
CAS No. | 2151853-97-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90 mg/mL (306.83 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.4092 mL | 17.0462 mL | 34.0925 mL | 85.2311 mL |
5 mM | 0.6818 mL | 3.4092 mL | 6.8185 mL | 17.0462 mL | |
10 mM | 0.3409 mL | 1.7046 mL | 3.4092 mL | 8.5231 mL | |
20 mM | 0.1705 mL | 0.8523 mL | 1.7046 mL | 4.2616 mL | |
50 mM | 0.0682 mL | 0.3409 mL | 0.6818 mL | 1.7046 mL | |
100 mM | 0.0341 mL | 0.1705 mL | 0.3409 mL | 0.8523 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
MPT0G211 2151853-97-1 Chromatin/Epigenetic DNA Damage/DNA Repair HDAC Inhibitor inhibitor inhibit